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COMMENTARY
   Reporting research antibody use: how to increase
 experimental reproducibility [v2; ref status: indexed, 
http://f1000r.es/1np]
Matthew A Helsby , Joe R Fenn , Andrew D Chalmers1,2 1,2 1,2
Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, UK1
CiteAb, Bath, BA1 1UD, UK2
Abstract
Research antibodies are used in a wide range of bioscience disciplines, yet it is
common to hear dissatisfaction amongst researchers with respect to their
quality. Although blame is often attributed to the manufacturers, scientists are
not doing all they can to help themselves. One example of this is in the
reporting of research antibody use. Publications routinely lack key details,
including the host species, code number and even the company who supplied
the antibody. Authors also fail to demonstrate that validation of the antibodies
has taken place. These omissions make it harder for reviewers to establish the
likely reliability of the results and for researchers to reproduce the experiments.
The scale of this problem, combined with high profile concerns about
experimental reproducibility, has caused the Nature Publishing Group to
include a section on antibody information in their recent Reporting Checklist for
Life Science Articles. In this commentary we consider the issue of reporting
research antibody use and ask what details authors should be including in their
publications to improve experimental reproducibility.
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      Changes from Version 1
In producing the second version of our manuscript we followed 
suggestions from the reviewers and included more information 
and references regarding antibody validation. In addition, more 
emphasis on problems with batch-batch variability, the importance 
of knowing the antigen and a reference which shows good 
antibody reporting was added. We also added more emphasis 
on the fact that change is likely to require help from journals, 
specifically that they include antibody reporting guidelines in their 
instructions to authors.
Antibody information is routinely omitted from 
publications
Neuroscience, cancer research, regenerative medicine, infection 
and immunity, cell biology and cardiovascular research are just 
some of the fields in which research antibodies are commonly used. 
The sheer scale of their use is illustrated by huge sales, estimated 
to be worth in excess of $1.6 billion annually1. Despite, or perhaps 
because of this widespread use, it is common to hear dissatisfaction 
among research scientists about the quality of these antibodies2–4. 
The finger of blame is often pointed at the manufacturers, yet it 
is questionable whether scientists themselves are doing everything 
they can to help the situation; surely not all problems can be placed 
at the door of the antibody manufacturer. One example of scien-
tists not helping themselves is in their reporting of antibody use. 
There are many cases of good practice (For example5) and detailed 
reporting, but all too frequently authors omit key details. These 
include the host species and code numbers, but even the source of 
the antibody may be left out. This makes it harder for reviewers to 
establish how well characterised the antibodies are and thus how 
reliable the data presented are likely to be. It also makes it more 
difficult for other researchers to accurately reproduce experiments.
Failure to report key information is not a new problem2,6, but recent 
developments have increased efforts to find a solution. In particu-
lar, experimental reproducibility has been thrust into the limelight 
by high profile cases. For example, a study of “landmark” cancer 
research papers found that scientific findings from only 11% of 
them could be repeated7. Taken at face value this is a shocking 
statistic and, in an attempt to try to improve experimental repro-
ducibility, the Nature Publishing Group have recently introduced 
a reporting checklist for life science articles8. This checklist high-
lights research antibodies as a reagent type for which reporting 
could be improved. A key question is; what information to pro-
vide? In this commentary we consider what information authors 
should be including in their publications to help improve experi-
mental reproducibility.
Key details for reporting antibody experiments
Publications need to report core information regarding the antibod-
ies that were used. This should include the name of the antibody, 
the company/academic who supplied the antibody, the host spe-
cies in which the antibody was raised and whether the antibody 
is monoclonal or polyclonal. In addition, the catalogue or clone 
number needs to be mentioned. The catalogue or clone number is 
commonly omitted from current publications, but is important as 
large antibody companies will often have multiple antibodies to the 
same target, a unique identifier is therefore essential to allow unam-
biguous identification of the antibody concerned. For this reason the 
first step in improving reporting should be to make it mandatory for 
authors to include core antibody information, including a code or 
clone number for the antibodies they use.
A second type of information that should be reported relates to 
experimental details. The application the antibody was used for is 
of central importance. This information is normally present, but 
it can be hard to extract if the antibody information is listed in a 
‘Materials’ section and separated from descriptions of the tech-
niques. Having the antibody data and application data closely 
linked would avoid potential confusion. Furthermore, if a study 
uses samples from more than one species then it is also important to 
clearly link which antibodies were used in which species.
There are other features that could also be reported which may be 
particularly relevant to certain studies. For example, the antibody 
batch number is rarely included in methods sections, but it is com-
mon to hear concern about variability between different antibody 
batches. This if often anecdotal, but there are some published 
examples9,10. This type of variability is likely to be a particular issue 
with polyclonal antibodies2, but may affect monoclonal antibod-
ies11. We encourage scientists to report cases in which variability 
has been found and in these examples include batch numbers. Re-
porting the final antibody concentration or dilution is another piece 
of information which can help other researchers, especially if opti-
misation was required during the study.
It has been proposed that scientists should know the antigen which 
was used to raise the antibody3. There are exceptions, for example 
where antibodies have been raised from a cell/tissue lysate and the 
antigen is unknown, but for most cases the antigen or at least its 
location within the protein should be known, as it may have impli-
cations for interpretation of the results. In cases where it is relevant 
to the study authors should be encouraged to report the antigen 
location. Finally, there will be details of particular importance for 
individual techniques, we focus on research antibodies, but studies 
reporting therapeutic use would be an example in which specific 
details such as purity and dose need to be reported.
Antibody validation
The Nature Publishing Group checklist, mentioned above, requires 
authors to demonstrate that every antibody used in their study has 
been validated for use in each of the specific experiments and species 
used. The experimental process of antibody validation is complex, 
with the most rigorous methods being comparison of wildtype vs a 
knockdown/knockout tissue and/or use of a second antibody to dif-
ferent epitope. The validation must also be carried out for each exper-
imental setup as specificity in one application, or even fixative, does 
not mean an antibody will be specific in another. It is also the case 
that the details that should be reported to demonstrate validation will 
be different for each application. For more information on antibody 
validation we highly recommend the following publications12–18.
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Our focus is on how to report antibody validation, which can be 
achieved in a number of ways. If an antibody has not been previously 
validated for the specific combination of application and species 
used, then it should be mandatory that validation be carried out and 
reported. This can often be included as supplementary information.
If the antibody has previously been validated then one or more cita-
tions could be given to highlight the validation. Alternatively, the 
publication could reference the antibody validation profile from 
publicly available databases such as 1degreebio, Antibodypedia, 
CiteAb or pAbmAbs (A more extensive list of databases is available 
from Pivotal Scientific). Again it is important that antibody suppli-
ers and codes are used in publications so that each antibody can be 
unambiguously identified and the degree of previous characterisa-
tion assessed. If new validation has been carried out then this could 
also be deposited in a public database and the database cited, instead 
of or in addition to putting the data in the supplementary informa-
tion. Including information to show validation has occurred would 
help reviewers and other researchers accurately assess the results.
Change will require help from journals and reviewers
It seems likely that significant change is not going to occur unless 
journals take a lead and encourage it by adding antibody reporting 
guidelines to their instructions to authors. The success of this has 
been demonstrated by the Journal of Comparative Neurology which 
has had extensive guidelines in place since 2006 and the Journal 
of Visualised Experiments which requires a table of materials, 
including catalogue numbers for all the reagents used, to be report-
ed. The Nature Publishing Group checklist should improve report-
ing in their journals and it is encouraging to see that following pub-
lication of version 1 of this manuscript F1000Research and PeerJ 
have added our proposed guidelines to their instructions for authors 
(described below). Once a journal has added guidelines it will be 
crucial that peer-reviewers are encouraged to evaluate the reporting 
and enforce the guidelines.
A simple format for reporting antibody information
Based on the points discussed above we would suggest that journals 
adopt, and researchers use, the format shown in Box 1.
This format is meant as a guide and could be adapted as required; 
for example details of batch number, dilution or epitope could be 
added where particularly important. This information could also 
be usefully presented in a table if allowed by the journal. Adop-
tion of these reporting guidelines will not eliminate researchers’ 
frustrations with antibodies, but should help improve experimental 
reproducibility and scientists’ productivity, something we all seek. 
An additional benefit for authors who include this information is 
that well annotated publications are easier for antibody companies 
and antibody search engines to highlight in their databases. This 
inclusion is likely to increase the number of researchers who access 
their work and so potentially the impact of the study.
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Box 1. Suggested format for reporting antibody information
Publications using commercial antibodies should report the 
supplier and the code number. Publications using academic 
antibodies should report the source laboratory and relevant 
reference. We recommend the following format;
“The following antibodies were used, Mouse anti-protein A 
monoclonal antibody (Company E, catalogue number #1000) 
was used for ELISA with human cells as validated in (figure X or 
reference Y or validation profile Z) and western blotting in mouse 
tissue as validated in (figure X or reference Y or validation profile Z).
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   Current Referee Status:
Referee Responses for Version 2
 David Soll
University of Iowa, Iowa City, IA, USA
Approved: 01 October 2013
 01 October 2013Referee Report:
I am happy with the changes and I find the paper acceptable.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 Simon Glerup
Department of Biomedicine, Aarhus University, Aarhus, Denmark
Approved: 09 September 2013
 09 September 2013Referee Report:
No further revision required.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Referee Responses for Version 1
 Simon Glerup
Department of Biomedicine, Aarhus University, Aarhus, Denmark
Approved: 01 August 2013
 01 August 2013Referee Report:
This commentary is much needed in the field of life science. It is well written and concise. Andrew
Chalmer’s group has contributed significantly to the use of research antibodies by creating CiteAb. When
operating the CiteAb search engine, I imagine that they constantly run into problems with publications with
poorly described use of research antibodies.
I have two minor suggestions: 
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1.  
2.  
I have two minor suggestions: 
In the Antibody Validation paragraph, a statement could be included in the methods section of a
paper regarding if, where and under what name antibody validation information or reviews has
been posted in publically available databases. This would increase the value and transparency of
these databases.
Unlike the previous reviewer, I think it is fine to mention CiteAb in the paper. After all, even Nature
Publishing Group is a highly commercial enterprise. However, I suggest that a table could be
included listing the relevant databases including CiteAb, pAbmAbs, Biobrea, Antibodypedia,
1degreebio, Antibody-Advizer etc. In this regard, I regret that the Checklist from Nature Publishing
Group only refers to sites in which they have a commercial interest (1degreebio and
Antibodypedia). I hope that other publishing groups are not tempted to do the same.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
, University of Bath, UKAndrew Chalmers
Posted: 03 Sep 2013
We thank Professor Glerup for his helpful comments and share his concern about the Nature
Publishing Group guidelines. We explain our response to each one in turn below. 
The fact that if no previous validation has occurred then it should be carried out and
reported and/or submitted to a public database has been made clearer.  
This is a good point and we agree it is important to give an overview of available databases
to allow readers to choose the most appropriate. For this reason we were careful to mention
a range in our first version. However, we feel it would not be appropriate for us to compile a
table given our clear affiliation to one database, instead we provide a link to the most
complete list of databases we are aware of.
 No competing interests were disclosed.Competing Interests:
 John Colyer
University of Leeds, Leeds, UK
Approved: 24 July 2013
 24 July 2013Referee Report:
The title and abstract are clear and appropriate. The article is timely and written clearly and accessibly. 
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The title and abstract are clear and appropriate. The article is timely and written clearly and accessibly. 
It could be improved further by providing references for papers that are examples “of good practice
and detailed reporting”, which might serve as a template for others.
The process of antibody validation is worthy of more extensive discussion, as the research
community needs to develop a clear understanding of the most appropriate tests to be performed
in each experimental system, and standards which should be attained for acceptance of the status
of “validated”.  This data should be provided in supplementary data, or by reference to previous
supplementary data if the same reagents are used in a new study.
The importance of batch number is made, but could be emphasized more.
Finally, the critical role of peer-reviewers in evaluating and enforcing these standards is key. Some
discussion of this would enhance the manuscript.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
, University of Bath, UKAndrew Chalmers
Posted: 03 Sep 2013
We thank Professor Colyer for his positive and helpful comments and explain our response to each
one in turn below.
A good idea, we have now added an example reference that illustrates good reporting
practice (Antibody information is routinely omitted from publications’ section). Journals
which already encourage good practice have also been highlighted (‘Change will require
help from journals and reviewers’).  
We completely agree and have increased the amount we cover on this topic, but not
attempted a full review as we feel such a complex topic is beyond the scope of this
comment article. We have added some additional citations for readers who require more
information (Antibody Validation section).
The fact that if no previous validation has occurred then it should be carried out and
reported and/or submitted to a public database has been made clearer. The fact that
previous validation can be cited has also been spelled out (Antibody Validation section).
Additional emphasis has been added regarding the problem of batch to batch variability
(‘Key details for reporting antibody experiments’ section).
This has been added to the ‘Change will require help from journals and reviewers’ section.
 No competing interests were disclosed.Competing Interests:
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 David Soll
University of Iowa, Iowa City, IA, USA
Approved with reservations: 16 July 2013
 16 July 2013Referee Report:
This commentary is timely and well written, but it could be shortened or tightened up a bit for the purpose
of conciseness.  It also should include a few points noted in this review.  The major point is the problem
that lack of information in publications involving research antibodies affects assessment and future use.
 The discussion could be more efficient in stating that if methods were reported in a previous referenced
article, then referencing that article in a new publication is sufficient, unless there are nuances (i.e., new
uses of the antibody).  It should also be made clear that such information be mandatory when an antibody
is used in a particular way for the first time.  
There are also a few things the author may want to include: 
Many antibodies work on a particular protein in a particular cell type without knowledge of the
protein domain(s) found.  In spite of that they may be of value, so you don’t have to identify the
sequence molecule. 
Some antibodies identify native conformation and therefore are not on a peptide sequence per se. 
Such antibodies are not unusually performed on denatured proteins in western blots, but may work
in nature gels. 
Some antibodies have not been fully characterized beyond reference to the data sheet provided by
the company or source if necessary. 
 If the authors of a paper refer to the company, and catalog name of the antibody, prior
characterization can access.
Antibody validation should go in the supplementary data to a paper.
Do not cite CiteAb in your paper - it sounds like an ad. 
But all in all, this is a reasonable commentary.  It reinforces what many already are advocating. The title
and abstract were fine.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
1 Comment
Author Response
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Author Response
, University of Bath, UKAndrew Chalmers
Posted: 03 Sep 2013
We thank Professor Soll for his positive review and helpful comments. We have now addressed
them and explain our response to each one in turn below: 
‘The discussion could be more efficient in stating that if methods were reported in a previous
referenced article....’ 
The fact that previous validation can be cited has now been spelled out more clearly (Antibody
Validation section). 
‘...information be mandatory when an antibody is used in a particular way for the first time’
The fact that if no previous validation has occurred then validation should be carried out and
reported and/or submitted to a public database has been made clearer (Antibody Validation
section). These are two key points and we appreciate the fact you raised them.
Things we have now included to respond to the numbered points raised. 
More discussion of the importance of knowing the antigen for an antibody has been added,
in particular raising the point that for some antibodies the antigen is not known, for example
when they are raised to a complex cell or tissue lysate (key details for reporting antibody
experiments section).  
This comment is relevant to the experimental validation of antibodies, we have increased
the amount we cover on this topic but not attempted a full review as we feel such a complex
topic is beyond the scope of this comment article. We have added some addition citations
for readers who require more information (Antibody Validation section).
We have made it clearer when validation should be carried out and how it should be
reported if no previous validation has taken place (Antibody Validation section).
We have now repeated the importance of including catalogue numbers in the antibody
validation section.  
This is now made clear (Antibody Validation section).  
We think giving examples of available antibody databases will be useful to readers and
were careful to mention more than one database, we have now added a link to a more
extensive list. We have also removed the second reference to CiteAb which was in the final
section.
 No competing interests were disclosed.Competing Interests:
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Article Comments
Comments for Version 2
Author Response
, University of Bath, UKAndrew Chalmers
Posted: 06 Mar 2014
Dear Mark,
That is an interesting observation; including catalogue codes is a big step forward in terms of being able to
identify the reagents used, but I don't have any news on their approach to whether validation information is
required. It sounds like your observations suggests not.
 No competing interests were disclosed.Competing Interests:
, Institut Pasteur, FranceMark Livingstone
Posted: 25 Feb 2014
I'm interested to know how the  checklist is being used today. Looking through the articlesNature
published, I find no evidence of antibody validation using knockout/knockdown cells and tissues. It seems
they have settle for publishing catalogue numbers of antibodies, and maybe they don't require that "
Antibodies should have been profiled to determine their sensitivity, specificity and range of reactivity in the
 Is there any news?assay being considered".
 No competing interests were disclosed.Competing Interests:
Author Response
, University of Bath, UKAndrew Chalmers
Posted: 20 Sep 2013
An interesting recent paper quantifies the % of antibodies that can be identified from scientific publications
and found only 46% could be identified, with only 27% using code numbers.
https://peerj.com/articles/148/
 No competing interests were disclosed.Competing Interests:
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Author Response
, University of Bath, UKAndrew Chalmers
Posted: 16 Sep 2013
Dear Professor Finger we thank you for your support for our article and interesting comments. We
absolutely agree about the importance of the antigen. Regarding newly generated antibodies, the simplest
way might be for batch numbers to correspond to each uniquely raised antibody sample and for authors to
report batch numbers. We discussed both issues in the article but decided not to include them in our core
guidelines, instead mentioning them as additional things which could/should be reported. We felt that
keeping the core guidelines to a minimum would make it more likely that they would be adopted by
journals that do not currently have any guidelines. However, we agree in an ideal world all journals would
have more extensive guidelines, such as found in The Journal of Comparative Neurology.
 No competing interests were disclosed.Competing Interests:
, School of Medicine, Department of Cell and Developmental Biology, University ColoradoThomas Finger
Denver, USA
Posted: 07 Sep 2013
The point made by this article is very important and cannot be emphasized enough. Articles that report
results using unspecified reagents (e.g. antisera) are simply not repeatable. A significant problem with the
minimum standards suggested in this article is the omission of specification of the antigen employed to
generate each particular antiserum and whether the product has been affinity purified. The selection of
antigen is crucial for interpretation of results since the nature of the antigen will determine to a large extent
the degree of cross-reactivity (both in terms of cross species and across proteins) of the product.  While
specification of a catalogue number and supplier will usually allow a reader to obtain this information for
currently marketed antisera, once the company removes the antiserum from the market or even ends
commercial activity, the antigen information is usually difficult or impossible to obtain. Accordingly, detailed
information on the nature of the antigen should be included in all published reports.  I encourage the
authors to modify their guidelines to embrace this additional requirement. 
Further, manufacturers should indicate, perhaps by a suffix to a catalogue number, if an antibody has been
newly generated even if using the same antigen as previously. We have now had several experiences of
ordering the same product number and having the new antiserum fail. Upon enquiry from the source, we
are told that this is a new batch generated by immunizing a new set of animals. I would argue that this is no
longer the same reagent and therefore should be assigned a different catalogue number. The new lot
would need to be validated entirely as if a new product were being tested.
 Associate editor, J. Comp. Neurol.Competing Interests:
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Comments for Version 1
, PhosphoSolutions, USAMike Browning
Posted: 12 Jul 2013
I would like to compliment the authors on their very informative and timely article. I also heartily endorse
their “Format for Reporting Antibody Information”. A key feature of this recommendation is that authors
report the catalog number of the antibody they use. This is a very important recommendation for authors,
but in my opinion, this format is only useful if antibody vendors also implement certain standard practices.
Obviously vendors must never substitute a new antibody source for an existing catalog number. Moreover
it is especially important in polyclonal antibodies that vendors insure that all batches of the polyclonal
come from the same pool of antisera and never from different bleeds from the same rabbit. If these two
provisions are followed then many of the problems with batch to batch variation in antibodies can be
eliminated.
 CEO and owner of PhosphoSolutions LLC a manufacturer of antibodies, especiallyCompeting Interests:
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